US pauses use of Eli Lilly's Covid-19 treatment nationwide due to variants

Due to the presence of variants, the US said Friday that it’s pausing shipments of Eli Lilly’s monoclonal antibody combo for the treatment of Covid-19 on a national basis until further notice.

The pause, which could amount to the loss of about $375 million in sales according to one biotech analyst, is another blow to Lilly’s efforts to treat Covid-19 outside of the hospital, as the company previously had its EUA for bamlanivimab revoked.